Safety, Efficacy and Bioavailability of Fixed Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review

Publication date: Available online 2 February 2017 Source:Current Therapeutic Research Author(s): Thangavel Mahalingam Vijayakumar, Jayasutha Jayaram, Vishnu Meghana Cheekireddy, Dasari Himaja, Yalamanchili Dharma Teja, Damodharan Narayanasamy Purpose Type 2 diabetes mellitus (T2DM) is a multifactorial disease characterized by insulin resistance. As time progresses, monotherapy often does not provide effective glycemic control generating the need for an add-on therapy. Hence, multiple oral hypoglycemic agents formulated as a single dosage form called “Fixed-Dose Combinations” (FDCs) play an essential role in glycemic control. The purpose of this systematic review is to appraise the recently published evidence on safety, efficacy, and bioavailability of FDCs. Methods A comprehensive literature search of PUBMED, SCOPUS, SCIENCEDIRECT, PROQUEST, SPRINGER LINK, CLINTRIALS.GOV,EMBASE and EBSCO using the keywords FDCs, Combination therapy, T2DM management and add-on therapy was conducted. Studies on safety profile/tolerability, efficacy, and bioavailability of various FDCs of oral hypoglycemic agents were preferred. Findings The systematic review of all the publications suggests that FDCs of Oral Hypoglycemic agents (OHAs) significantly reduce HbA1C and FPG values, thereby efficiently reducing hyperglycemia in patients failing on monotherapy. FDCs are bioequivalent to the concomitant drugs administered as individual components. Improved adherence of FDCs and absence o...
Source: Current Therapeutic Research - Category: Drugs & Pharmacology Source Type: research